High-quality
real-world data
Generating high-validity real-world evidence requires high-quality RWD.
Accelerate clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across all therapeutic areas using credible evidence developed from high-quality real-world data with measured accuracy, completeness, and traceability.
High-quality
real-world data
Generating high-validity real-world evidence requires high-quality RWD.
Accelerate clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across all therapeutic areas using credible evidence developed from high-quality real-world data with measured accuracy, completeness, and traceability.
New times call for a powerful platform
For biopharma decision-makers, Verantos is making what seemed impossible, possible. Our high-validity RWE platform combines deep phenotyping — structured and unstructured data from electronic health records (EHR), artificial intelligence (AI), and accuracy determination — with linkage to exposure and outcomes data to answer today’s most challenging clinical questions.
Our Awards
Meet increasing RWE demands
High-validity RWE – utilizing the entire patient record, deep phenotyping, AI-generated insights, and linked exposures and outcomes – makes it possible to understand how patient characteristics and behaviors affect health outcomes to predict the progression of a disease and a patient’s responses to therapy while also increasing the efficiency of R&D investments and accelerating time to market.
Get out of the danger zone
Studies based on traditional RWE leave franchises vulnerable to regulatory and market access concerns and commercial delay. High-validity studies run on our high-validity RWE platform provide accurate and believable evidence, enabling regulatory and reimbursement approvals. It is worth investing now in the RWE capabilities of the future.
Our Partners
